Topic: cardiovascular outcomes
The ADA's treatment recommendation could help drive Vascepa sales past Amarin's $350 million projection for the year, an analyst says.
The fish oil-derived drug showed significant reduction not just in first cardiovascular events, but in recurrent incidence as well.
After AstraZeneca released overall CV outcomes results for Farxiga, the company has dug further into the data and presented two subanalyses on Monday.
Some critics said the abnormal trends in key CV biomarkers in the placebo arm has compromised the otherwise exciting data.
All eyes are on Eli Lilly’s Trulicity as it faces down new competition. But the drugmaker just notched an important trial win that shows it can hang with its rival.
It’s been more than a year since J&J showed Invokana could improve heart safety, but the company's reps can finally tout those benefits.
Lilly and BI's Tradjenta is working to pick up share in a competitive diabetes market, and it’s hoping new outcomes data can help it do exactly that.
Call it a promise kept. Amarin has staunchly promised that Vascepa could prove it cuts heart risks, despite detractors' disbelief—and now it has.
Sanofi and Regeneron are ready to wheel and deal if they win the FDA's blessing to tout their cholesterol drug Praluent's cardiovascular benefits.
The 2018 European Society of Cardiology Congress presented some bombshell data that would shake up the cardiovascular landscape in the coming year.